MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Strona główna・Stock List・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Closed

SectorHealthcare

24.09 2.73

Buy Sell

Overview

Share price change

24h

Current

Min

23.42

Max

24.63

Key metrics
By Trading Economics
Income	-14M -50M
Sales	12M 128M
Profit margin	-39.506
Employees	1,784
EBITDA	-17M -48M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+46.6% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	200M 2.4B
Previous open	21.36
Previous close	24.09

News Sentiment

By Acuity

42%

58%

147 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

28.13 / 31.12 Support & Resistance

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 kwi 2026, 20:26 UTC

Acquisitions, Mergers, Takeovers

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 kwi 2026, 18:15 UTC

Major News Events

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 kwi 2026, 16:49 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17 kwi 2026, 16:49 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17 kwi 2026, 22:58 UTC

Earnings

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 kwi 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 kwi 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 kwi 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17 kwi 2026, 20:52 UTC

Earnings

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 kwi 2026, 20:50 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

17 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 kwi 2026, 20:29 UTC

Earnings

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 kwi 2026, 20:11 UTC

Acquisitions, Mergers, Takeovers

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 kwi 2026, 19:34 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

17 kwi 2026, 19:34 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 kwi 2026, 19:31 UTC

Market Talk

Major News Events

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 kwi 2026, 19:26 UTC

Market Talk

U.S. Natural Gas Futures Edge Up -- Market Talk

17 kwi 2026, 19:21 UTC

Market Talk

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 kwi 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 kwi 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 kwi 2026, 18:57 UTC

Major News Events

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 kwi 2026, 18:53 UTC

Acquisitions, Mergers, Takeovers

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 kwi 2026, 18:53 UTC

Acquisitions, Mergers, Takeovers

UCB 2026 Rev Guidance Unchanged

17 kwi 2026, 18:52 UTC

Acquisitions, Mergers, Takeovers

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 kwi 2026, 18:52 UTC

Acquisitions, Mergers, Takeovers

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 kwi 2026, 18:14 UTC

Market Talk

Major News Events

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 kwi 2026, 18:00 UTC

Major News Events

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 kwi 2026, 18:00 UTC

Major News Events

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 kwi 2026, 17:31 UTC

Market Talk

Major News Events

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 kwi 2026, 17:26 UTC

Market Talk

Earnings

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

46.6% upside

12 Months Forecast

Average 34.45 USD 46.6%

High 47 USD

Low 21.8 USD

Based on 4 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Zai Lab Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

147 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.